Furthermore, K252a treatment decreased transcript levels of an endothelial cell marker, CD31, and a proangiogenic factor, VEGF-A (Fig. 5D) in metastatic tumors, suggesting inhibition of angiogenesis. The gene discussed is VEGFA; the disease is metastatic neoplasm.